Presentation:
Long-acting injectable cabotegravir as pre-exposure prophylaxis for HIV prevention (LAI CAB PrEP) has been FDA approved in the U.S. since December 2021. Approvals are in place or pending in many countries and regions globally, and it is being evaluated for programmatic implementation in a variety of contexts. Since FDA approval in the U.S., LAI CAB PrEP implementation and scale-up has been relatively slow across the nation. In this presentation, we will highlight the challenges and opportunities in LAI CAB PrEP program initiation and describe select strategies that have supported successful programs.